Outcomes of seromuscular bladder augmentation compared with standard bladder augmentation in the treatment of children with neurogenic bladder

Table 1 Demographic characteristics of the patients and concomitant surgery in the 2 groups, n (%)

	Total patients	Sex (male/female)	Age at surgery (yr)	Follow-up duration (mo)	Ureteral reimplantation	Continent catheterizable channel
SC	46	21/25	10.6	36	32 (70.0)	19 (41.3)
SMBA	21	8/13	7.6	29.7	18 (85.7)	2 (9.5)

SC: Standard cystoplasty; SMBA: Seromuscular bladder augmentation.

Table 2 Urodynamic parameters of the patients in the 2 groups before and after surgery

	Pre capacity (mL)	Post capacity (mL)	Pre compliance (mL/cm H2O)	Post compliance (mL/cm H2O)	Pre pressure (cm H2O)	Post pressure (cm H2O)
SC	173.9	387.0	4.8	26.7	44.9	20.7
SMBA	151.7	200.4	3.5	6.0	50.2	34.3
P value	0.26	0.000	0.19	0.000	0.28	0.000

Pre: Preoperative; Post: Postoperative; SC: Standard cystoplasty; SMBA: Seromuscular bladder augmentation.

Table 3 Incontinence, number of clean intermittent catheterizations and oral anticholinergic drugs in the 2 groups, n (%)

	Pre incontinence	Post incontinence	Number of CICs	Oral anticholinergic drugs
SC	32 (69.6)	3 (6.5)	5.6	8 (17.4)
SMBA	18 (85.7)	7 (33.3)	7.6	17 (81.0)
P value	0.229	0.008	0.000	0.000

Pre: Preoperative; Post: Postoperative; SC: Standard cystoplasty; SMBA: Seromuscular bladder augmentation; CIC: Clean intermittent catheterization.

Table 4 Postoperative complications in the 2 groups, n (%)

	Intestinal obstruction	Leakage	Incision infection	Recurrent UTIs	Bladder calculi	Residual reflux	Reaugmentation
SC	2 (4.3)	4 (8.7)	6 (13.0)	4 (8.7)	3 (6.5)	1 (2)	0
SMBA	1 (4.8)	5 (23.8)	6 (28.6)	2 (9.5)	1 (4.8)	7 (33.3)	6 (28.6)

SC: Standard cystoplasty; SMBA: Seromuscular bladder augmentation; UTIs: Urinary tract infections.